Does the media prefer EDIT or BEAM?

In the previous week, Editas Medicine and Editas Medicine both had 6 articles in the media. Beam Therapeutics' average media sentiment score of 0.62 beat Editas Medicine's score of -0.31 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRSP or EDIT?

In the previous week, CRISPR Therapeutics had 11 more articles in the media than Editas Medicine. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 6 mentions for Editas Medicine. CRISPR Therapeutics' average media sentiment score of 0.85 beat Editas Medicine's score of -0.31 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 11 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NTLA or EDIT?

In the previous week, Editas Medicine had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 6 mentions for Editas Medicine and 4 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.46 beat Editas Medicine's score of -0.31 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, COAG or EDIT?

Hemab Therapeutics has higher earnings, but lower revenue than Editas Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Editas Medicine $40.52M 6.38 -$160.06M -$1.23 N/A

Does the media refer more to COAG or EDIT?

In the previous week, Editas Medicine had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Editas Medicine and 3 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.00 beat Editas Medicine's score of -0.31 indicating that Hemab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, EDIT or HROW?

Harrow has higher revenue and earnings than Editas Medicine. Harrow is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Editas Medicine $40.52M 6.38 -$160.06M -$1.23 N/A Harrow $272.30M 4.53 -$5.14M -$0.41 N/A

Is EDIT or HROW more profitable?

Harrow has a net margin of -5.57% compared to Editas Medicine's net margin of -281.59%. Harrow's return on equity of 19.59% beat Editas Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Editas Medicine -281.59% -677.39% -58.25% Harrow -5.57% 19.59% 2.26%

Does the media refer more to EDIT or HROW?

In the previous week, Editas Medicine had 3 more articles in the media than Harrow. MarketBeat recorded 6 mentions for Editas Medicine and 3 mentions for Harrow. Harrow's average media sentiment score of 0.06 beat Editas Medicine's score of -0.31 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Editas Medicine (EDIT) Competitors

$2.64 -0.07 (-2.58%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$2.66 +0.02 (+0.95%)

As of 06/8/2026 07:29 PM Eastern

Compare

EDIT vs. BEAM, CRSP, NTLA, COAG, and HROW

Should you buy Editas Medicine stock or one of its competitors? MarketBeat compares Editas Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Hemab Therapeutics (COAG), and Harrow (HROW). These companies are all part of the "pharmaceutical products" industry.

How does Editas Medicine compare to Beam Therapeutics?

Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

In the previous week, Editas Medicine and Editas Medicine both had 6 articles in the media. Beam Therapeutics' average media sentiment score of 0.62 beat Editas Medicine's score of -0.31 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a net margin of -39.66% compared to Editas Medicine's net margin of -281.59%. Beam Therapeutics' return on equity of -29.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Editas Medicine currently has a consensus target price of $5.40, suggesting a potential upside of 104.55%. Beam Therapeutics has a consensus target price of $46.83, suggesting a potential upside of 57.26%. Given Editas Medicine's higher possible upside, equities analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.38	-$160.06M	-$1.23	N/A
Beam Therapeutics	$139.74M	21.92	-$79.99M	-$0.68	N/A

Editas Medicine has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Beam Therapeutics beats Editas Medicine on 14 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,417.90	-$581.60M	-$6.22	N/A
Editas Medicine	$40.52M	6.38	-$160.06M	-$1.23	N/A

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CRISPR Therapeutics currently has a consensus price target of $65.47, indicating a potential upside of 26.88%. Editas Medicine has a consensus price target of $5.40, indicating a potential upside of 104.55%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

CRISPR Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

In the previous week, CRISPR Therapeutics had 11 more articles in the media than Editas Medicine. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 6 mentions for Editas Medicine. CRISPR Therapeutics' average media sentiment score of 0.85 beat Editas Medicine's score of -0.31 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Editas Medicine has a net margin of -281.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Editas Medicine	-281.59%	-677.39%	-58.25%

Summary

Editas Medicine beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Editas Medicine had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 6 mentions for Editas Medicine and 4 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.46 beat Editas Medicine's score of -0.31 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Editas Medicine has a net margin of -281.59% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Editas Medicine	-281.59%	-677.39%	-58.25%

Intellia Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

Editas Medicine has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	27.85	-$412.69M	-$3.54	N/A
Editas Medicine	$40.52M	6.38	-$160.06M	-$1.23	N/A

Intellia Therapeutics presently has a consensus target price of $20.25, indicating a potential upside of 50.11%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 104.55%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Intellia Therapeutics and Editas Medicine tied by winning 8 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Editas Medicine (NASDAQ:EDIT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, Editas Medicine had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Editas Medicine and 3 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.00 beat Editas Medicine's score of -0.31 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics presently has a consensus target price of $41.75, indicating a potential upside of 63.41%. Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 104.55%. Given Editas Medicine's higher probable upside, analysts plainly believe Editas Medicine is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Hemab Therapeutics has higher earnings, but lower revenue than Editas Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Editas Medicine	$40.52M	6.38	-$160.06M	-$1.23	N/A

Hemab Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Hemab Therapeutics' return on equity of 0.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Editas Medicine	-281.59%	-677.39%	-58.25%

71.9% of Editas Medicine shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Editas Medicine beats Hemab Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Editas Medicine compare to Harrow?

Editas Medicine (NASDAQ:EDIT) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Editas Medicine has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market. Comparatively, Harrow has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Harrow has higher revenue and earnings than Editas Medicine. Harrow is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.38	-$160.06M	-$1.23	N/A
Harrow	$272.30M	4.53	-$5.14M	-$0.41	N/A

In the previous week, Editas Medicine had 3 more articles in the media than Harrow. MarketBeat recorded 6 mentions for Editas Medicine and 3 mentions for Harrow. Harrow's average media sentiment score of 0.06 beat Editas Medicine's score of -0.31 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Harrow has a net margin of -5.57% compared to Editas Medicine's net margin of -281.59%. Harrow's return on equity of 19.59% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Harrow	-5.57%	19.59%	2.26%

Editas Medicine presently has a consensus target price of $5.40, indicating a potential upside of 104.55%. Harrow has a consensus target price of $69.43, indicating a potential upside of 109.75%. Given Harrow's stronger consensus rating and higher probable upside, analysts clearly believe Harrow is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Harrow beats Editas Medicine on 12 of the 16 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDIT vs. The Competition

Export

Metric	Editas Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$265.33M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	-2.15	18.61	23.92	23.74
Price / Sales	6.38	298.40	507.55	107.94
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	9.43	8.04	10.28	6.78
Net Income	-$160.06M	$23.89M	$3.57B	$337.51M
7 Day Performance	-6.38%	-3.28%	0.28%	-2.34%
1 Month Performance	-15.11%	2.78%	3.27%	1.88%
1 Year Performance	36.79%	36.03%	22.22%	25.55%

Editas Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDIT Editas Medicine	3.069 of 5 stars	$2.64 -2.6%	$5.40 +104.5%	+38.2%	$265.33M	$40.52M	N/A	230	Gap Down
BEAM Beam Therapeutics	2.5151 of 5 stars	$28.96 -7.0%	$46.83 +61.7%	+60.3%	$3.20B	$139.74M	N/A	510	Gap Up
CRSP CRISPR Therapeutics	3.0484 of 5 stars	$52.02 -4.0%	$65.47 +25.9%	+23.3%	$5.23B	$3.51M	N/A	460
NTLA Intellia Therapeutics	2.7685 of 5 stars	$13.13 -4.4%	$20.25 +54.2%	+66.7%	$1.92B	$67.67M	N/A	600	Gap Up
COAG Hemab Therapeutics	4.3416 of 5 stars	$27.47 +1.3%	$41.75 +52.0%	N/A	$1.28B	N/A	N/A	72	Quiet Period Expiration Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDIT) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, COAG, and HROW

How does Editas Medicine compare to Beam Therapeutics?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Summary

How does Editas Medicine compare to Hemab Therapeutics?

Summary

How does Editas Medicine compare to Harrow?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, COAG, and HROW

How does Editas Medicine compare to Beam Therapeutics?

Does the media prefer EDIT or BEAM?

Is EDIT or BEAM more profitable?

Do analysts recommend EDIT or BEAM?

Which has preferable earnings and valuation, EDIT or BEAM?

Which has more volatility & risk, EDIT or BEAM?

Do institutionals & insiders have more ownership in EDIT or BEAM?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Which has higher earnings and valuation, CRSP or EDIT?

Do institutionals and insiders believe in CRSP or EDIT?

Do analysts prefer CRSP or EDIT?

Which has more volatility and risk, CRSP or EDIT?

Does the media refer more to CRSP or EDIT?

Is CRSP or EDIT more profitable?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Do insiders and institutionals believe in NTLA or EDIT?

Does the media refer more to NTLA or EDIT?

Is NTLA or EDIT more profitable?

Which has more risk & volatility, NTLA or EDIT?

Which has stronger earnings & valuation, NTLA or EDIT?

Do analysts prefer NTLA or EDIT?

Summary

How does Editas Medicine compare to Hemab Therapeutics?

Does the media refer more to COAG or EDIT?

Do analysts prefer COAG or EDIT?

Which has better earnings and valuation, COAG or EDIT?

Is COAG or EDIT more profitable?

Do institutionals & insiders believe in COAG or EDIT?

Summary

How does Editas Medicine compare to Harrow?

Do institutionals and insiders believe in EDIT or HROW?

Which has more volatility and risk, EDIT or HROW?

Which has higher earnings and valuation, EDIT or HROW?

Does the media refer more to EDIT or HROW?

Is EDIT or HROW more profitable?

Do analysts prefer EDIT or HROW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools